Drugs / Tolecizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07468630 | Apr → Dec 2026 expected | colon adenocarcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tolecizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07468630 ↗ |
| Action | Inhibit | “Tolecizumab (PCSK9 inhibitor)” NCT07468630 ↗ |
| Route | Subcutaneous | “Tolecizumab (PCSK9 Inhibitor) 600mg, subcutaneous injection” NCT07468630 ↗ |